About
About Zhuhai Sailong Pharmaceutical Co.,Ltd
Sailong Pharmaceutical Group Co.,Ltd. researches, develops, produces, markets, and services pharmaceutical intermediates, raw materials, and preparations in China. The company offers esomeprazole sodium, ornithine aspartate, thymus, argatroban, tigecycline, monosialotetrahexose ganglioside sodium, cerebroprotein hydrolysate, milrinone, parecoxib sodium, tranexamic acid, clindamycin phosphate, pantoprazole sodium products, etc. It provides its products for therapeutic areas, such as cardiovascular, cerebrovascular, nerve, digestive system, proton pump inhibitors, anti-infectives, anti-bleeding drugs, analgesics, and other fields. Sailong Pharmaceutical Group Co.,Ltd. was formerly known as Zhuhai Sailong Pharmaceutical Co.,Ltd. and changed its name to Sailong Pharmaceutical Group Co.,Ltd. in September 2021. The company was founded in 2002 and is based in Zhuhai, China.
Research context
Zhuhai Sailong Pharmaceutical Co.,Ltd appears in PyInvesting’s Shenzhen Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Visit company website
5 years, 7 months ago
Zhuhai Sailong Pharmaceutical Co.,Ltd is currently in a long term downtrend where the price is trading 1.9% below its 200 day moving average.
From a valuation standpoint, the stock is 23.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 7.4.
Zhuhai Sailong Pharmaceutical Co.,Ltd's total revenue sank by 51.1% to $38M since the same quarter in the previous year.
Its net income has dropped by 197.3% to $-8M since the same quarter in the previous year.
Finally, its free cash flow grew by 81.0% to $-8M since the same quarter in the previous year.
Based on the above factors, Zhuhai Sailong Pharmaceutical Co.,Ltd gets an overall score of 2/5.